Research programme: cancer therapeutics - BioLineRxAlternative Names: BL-2010; BL-2030; BL-3040; BL-4050; BL-5020; BL-M010; EDP 08; EDP 17; EDP 19; EDP 20; EDP 23; EDP 24; EDP-33
Latest Information Update: 08 Jan 2013
At a glance
- Originator BioLineRx
- Class Monoclonal antibodies
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Research Cancer